Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Famitinib||SHR1020|SHR-1020||FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-beta Inhibitor 13 RET Inhibitor 39 VEGFR2 Inhibitor 35 VEGFR3 Inhibitor 5||Famitinib (SHR1020) is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373, PMID: 30382933).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||not applicable||Famitinib||Phase I||Actionable||In a Phase I trial, renal carcinoma patients treated with Famitinib demonstrated a disease control rate of 87.5%, which included 50% (12/24) with a partial response and 37.5% (9/24) with stable disease, and a PFS of 10.7 mo and an OS of 33 mo (PMID: 24238512).||24238512|
|Unknown unknown||Advanced Solid Tumor||not applicable||Famitinib||Phase I||Actionable||In a Phase I trial, patients with advanced solid tumors had antitumor activity in response to the receptor tyrosine kinase inhibitor, famitinib (PMID: 24043137).||24043137|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|